The landscape of contemporary clinical trials for untreated metastatic clear cell renal cell carcinoma.

[1]  C. Porta,et al.  Efficacy of Nivolumab plus Ipilimumab According to Number of IMDC Risk Factors in CheckMate 214. , 2019, European urology.

[2]  B. Melichar,et al.  Tailored immunotherapy approach with nivolumab in advanced renal cell carcinoma (TITAN-RCC) , 2019, Annals of Oncology.

[3]  W. Rathmell,et al.  Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study. , 2019, The Lancet. Oncology.

[4]  C. Porta,et al.  Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial , 2019, The Lancet.

[5]  X. Mu,et al.  Biomarker analyses from JAVELIN Renal 101: Avelumab + axitinib (A+Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC). , 2019, Journal of Clinical Oncology.

[6]  Ronald C. Chen,et al.  PDIGREE: An adaptive phase III trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704). , 2019, Journal of Clinical Oncology.

[7]  T. Powles,et al.  Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal‐Cell Carcinoma , 2019, The New England journal of medicine.

[8]  R. Motzer,et al.  Avelumab plus Axitinib versus Sunitinib for Advanced Renal‐Cell Carcinoma , 2019, The New England journal of medicine.

[9]  C. Porta,et al.  Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale. , 2019, Future oncology.

[10]  K. Bensalah,et al.  Sunitinib Alone or after Nephrectomy in Metastatic Renal‐Cell Carcinoma , 2018, The New England journal of medicine.

[11]  J. Reeves,et al.  Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma , 2018, Nature Medicine.

[12]  Jing Yan,et al.  Targeting VEGF/VEGFR to Modulate Antitumor Immunity , 2018, Front. Immunol..

[13]  J. Roszik,et al.  mTOR at the Transmitting and Receiving Ends in Tumor Immunity , 2018, Front. Immunol..

[14]  Bohuslav Melichar,et al.  Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal‐Cell Carcinoma , 2018, The New England journal of medicine.

[15]  T. Choueiri,et al.  Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  P. Subedi,et al.  Survival among patients with advanced renal cell carcinoma in the pretargeted versus targeted therapy eras , 2015, Cancer medicine.

[17]  N. Rioux-Leclercq,et al.  Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated with Sunitinib Response in the Metastatic Setting , 2015, Clinical Cancer Research.

[18]  R. Motzer,et al.  Overall survival in renal-cell carcinoma with pazopanib versus sunitinib. , 2014, The New England journal of medicine.

[19]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[20]  C. Tangen,et al.  Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. , 2005, The Journal of urology.